332 related articles for article (PubMed ID: 16614610)
21. [TNF inhibitors for treatment of rheumatoid arthritis].
Otomo K; Koike T
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
[No Abstract] [Full Text] [Related]
22. Development of a preliminary US power Doppler composite score for monitoring treatment in PsA.
Gutierrez M; Di Geso L; Salaffi F; Bertolazzi C; Tardella M; Filosa G; Filippucci E; Grassi W
Rheumatology (Oxford); 2012 Jul; 51(7):1261-8. PubMed ID: 22378715
[TBL] [Abstract][Full Text] [Related]
23. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
[TBL] [Abstract][Full Text] [Related]
24. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
25. Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Sidiropoulos PI; Boumpas DT
Ann Rheum Dis; 2006 Jun; 65(6):701-3. PubMed ID: 16699049
[TBL] [Abstract][Full Text] [Related]
26. TNFalpha inhibition in psoriatic arthritis: cause for hope.
Zabraniecki L; Fournié B
Joint Bone Spine; 2001 Mar; 68(2):106-8. PubMed ID: 11324924
[No Abstract] [Full Text] [Related]
27. [Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases].
Lapadula G
Reumatismo; 2005; 57(4 Suppl):22-9. PubMed ID: 16385352
[TBL] [Abstract][Full Text] [Related]
28. Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.
Migliore A; Bizzi E; Broccoli S; Laganà B
Clin Rheumatol; 2012 Jan; 31(1):193-4. PubMed ID: 22005889
[No Abstract] [Full Text] [Related]
29. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
Koó E; Brodszky V; Péntek M; Ujfalussy I; Nagy MB; Gulácsi L
Orv Hetil; 2006 Oct; 147(41):1963-70. PubMed ID: 17120686
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
31. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases.
Wiedmann MW; Mössner J; Baerwald C; Pierer M
Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):295-314. PubMed ID: 19594416
[TBL] [Abstract][Full Text] [Related]
32. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
33. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
Haberhauer G; Strehblow C; Fasching P
Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
[TBL] [Abstract][Full Text] [Related]
34. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
35. Errors noted in: re: Migliore A, Bizzi E, Broccoli S Laganà (2011). Indirect comparison of etanercept, infliximab, and adalumimab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Published on line June 21st 2011.
O'Regan C
Clin Rheumatol; 2011 Dec; 30(12):1647-8. PubMed ID: 21938451
[No Abstract] [Full Text] [Related]
36. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.
Eng G; Stoltenberg MB; Szkudlarek M; Bouchelouche PN; Christensen R; Bliddal H; Marie Bartels E
Semin Arthritis Rheum; 2013 Oct; 43(2):144-51. PubMed ID: 23838092
[TBL] [Abstract][Full Text] [Related]
37. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
[TBL] [Abstract][Full Text] [Related]
38. [Biologics in the treatment of psoriasis].
Dissemond J; Grabbe S
MMW Fortschr Med; 2006 Sep; 148(38):42-4. PubMed ID: 17036963
[TBL] [Abstract][Full Text] [Related]
39. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator.
Migliore A; Bizzi E; Broccoli S; Laganà B
Clin Rheumatol; 2012 Jan; 31(1):133-7. PubMed ID: 21701796
[TBL] [Abstract][Full Text] [Related]
40. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
González-Gay MA; Agudo M
Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
